ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 16 for:    "Muckle-Wells syndrome"
Previous Study | Return to List | Next Study

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome (REMITTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00465985
Recruitment Status : Completed
First Posted : April 27, 2007
Results First Posted : February 11, 2011
Last Update Posted : August 28, 2017
Sponsor:
Information provided by (Responsible Party):
Novartis

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Muckle Wells Syndrome
Interventions: Drug: ACZ885
Drug: Placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ACZ885 ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.
Placebo Placebo subcutaneous injection every 8 weeks.

Participant Flow for 3 periods

Period 1:   Part I - Open-label Treatment Period
    ACZ885   Placebo
STARTED   35 [1]   0 
COMPLETED   31 [2]   0 
NOT COMPLETED   4   0 
Unsatisfactory therapeutic effect                4                0 
[1] All patients received treatment with ACZ885 in Part I of the study.
[2] Only patients with a complete response completed Part I and entered Part II of the study.

Period 2:   Part II - 1:1 ACZ885:Placebo
    ACZ885   Placebo
STARTED   15 [1]   16 
COMPLETED   15   4 
NOT COMPLETED   0   12 
Unsatisfactory therapeutic effect                0                12 
[1] Patients with complete response to treatment entered Part II and were randomized to ACZ885 ,placebo.

Period 3:   Part III - Open-label Treatment Period
    ACZ885   Placebo
STARTED   31 [1]   0 
COMPLETED   29   0 
NOT COMPLETED   2   0 
Unsatisfactory therapeutic effect                1                0 
Adverse Event                1                0 
[1] All patients received treatment with ACZ885 in Part III of the study.



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ACZ885 ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.

Baseline Measures
   ACZ885 
Overall Participants Analyzed 
[Units: Participants]
 35 
Age 
[Units: Years]
Mean (Standard Deviation)
 34  (14.89) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      25  71.4% 
Male      10  28.6% 


  Outcome Measures

1.  Primary:   Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part)   [ Time Frame: 32 weeks after study start ]

2.  Primary:   Number of Participants Who Experienced a Disease Flare in Part II   [ Time Frame: 32 weeks after study start ]

3.  Secondary:   Number of Participants With Treatment Response in Part I (After 8 Weeks)   [ Time Frame: 8 weeks after study start ]

4.  Secondary:   Investigator's Clinical Assessment of Autoinflammatory Disease Activity & Participant's Assessment of Symptoms at End of Part II (After 24 Weeks of the Double-blind Part)   [ Time Frame: 32 weeks after study start ]

5.  Secondary:   Change in Inflammation Markers at the End of Part II (C-reactive Protein and/or Serum Amyloid A) (After 24 Weeks of the Double-blind Part) From Week 8.   [ Time Frame: Week 8 and Week 32 ]

6.  Secondary:   Pharmacokinetics (CLD (L/d))   [ Time Frame: 48 weeks after study start ]

7.  Secondary:   Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part I.   [ Time Frame: until Week 8 ]

8.  Secondary:   Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part II.   [ Time Frame: 32 weeks after study start ]

9.  Secondary:   Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part III.   [ Time Frame: 48 weeks after study start ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The outcomes for this study were reported in separate tables for each period. The SAE and AEs were reported in all in one table.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Study Director
Organization: Novartis Pharmaceuticals
phone: 862-778-8300


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT00465985     History of Changes
Other Study ID Numbers: CACZ885D2304
First Submitted: April 25, 2007
First Posted: April 27, 2007
Results First Submitted: November 16, 2010
Results First Posted: February 11, 2011
Last Update Posted: August 28, 2017